# Announcing the Third Annual Science in the City International Symposium in Paris > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/announcing-the-third-annual-science-in-the-city-international-symposium-in-paris/ > **Published:** 2026-06-25T23:14:17-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:21:20-04:00 > **Clinical Summary:** International cannabinoid therapeutics clinical education symposium advances physician training and evidence-based cannabis medicine integration globally. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchCBDTHCNeurologyMental HealthSafetyIndustry Why This Matters Clinicians attending this symposium can access updated evidence on cannabinoid safety and efficacy, which directly improves their ability to counsel patients on therapeutic applications versus risks. The focus on clinical integration provides practical frameworks for incorporating cannabis medicines into treatment protocols when appropriate for conditions like [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) or epilepsy. Physician education at this level addresses the current knowledge gap many clinicians face, enabling more informed prescribing decisions and better patient outcomes in jurisdictions where cannabis is therapeutically available. Clinical Summary The Third Annual Science in the City International Symposium in Paris will bring together leading researchers, clinicians, and pharmaceutical experts to advance cannabinoid therapeutics and clinical integration of cannabis-based medicines. This convening addresses a critical gap in physician education, as many clinicians lack formal training in [cannabis pharmacology](https://cedclinic.com/cannabis-tolerance-behavioral-models/), drug interactions, and evidence-based patient selection despite growing clinical applications. The symposium’s focus on clinical integration suggests emerging consensus on standardizing cannabinoid therapeutics within conventional medical practice, which could help legitimize cannabis as a therapeutic option while establishing quality and safety standards. For practicing physicians, participation in or awareness of such international scientific forums provides access to cutting-edge evidence and best practices in cannabinoid dosing, monitoring, and patient counseling. Clinicians seeking to responsibly incorporate cannabis into their practice should consider leveraging such educational symposia to develop competency in this rapidly evolving field. Dr. Caplan’s Take “These symposium gatherings serve an important function in our field, bringing together the peer-reviewed literature and clinical experience we need to advance [cannabinoid medicine](https://cedclinic.com/cannabinoids-prostate-cancer-anti-tumor-drugs/) responsibly, though I’d note that our evidence base remains uneven across different conditions, so the real work happens after the conference when we critically appraise what we heard against what the human trials actually show.” Clinical Perspective 🧠 While international symposia on cannabinoid therapeutics provide valuable forums for disseminating emerging research and fostering clinical dialogue, healthcare providers should recognize that attendance at such events, though intellectually stimulating, does not itself resolve the fundamental evidence gaps that currently limit cannabis-based treatment integration into mainstream practice. The heterogeneity of cannabis products, variable cannabinoid profiles, and limited high-quality [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) mean that enthusiasm at scientific conferences may outpace the actual evidence base available to individual practitioners making [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) decisions. Providers attending such meetings should maintain a critical stance toward claims about cannabinoid efficacy, carefully distinguishing between preliminary in vitro or animal data, small observational studies, and robust controlled trials that would support clinical recommendations. Practically speaking, clinicians can use these professional development opportunities to stay informed about the evolving regulatory and research landscape while tempering expectations about near-term clinical applications, and should continue to base cannabis-related counsel 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Announcing%20the%20Third%20Annual%20Science%20in%20the%20City%20International%20Symposium%20in%20Paris%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D66791)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D66791)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Announcing%20the%20Third%20Annual%20Science%20in%20the%20City%20International%20Symposium%20in%20Paris%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D66791)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.streetinsider.com/Newsworthy/Announcing+the+Third+Annual+Science+in+the+City+International+Symposium+in+Paris/26690255.html](https://www.streetinsider.com/Newsworthy/Announcing+the+Third+Annual+Science+in+the+City+International+Symposium+in+Paris/26690255.html) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).